Posted innews Respiratory
Brensocatib Shows Imaging Signals of Structural Benefit in Non‑CF Bronchiectasis: CT Substudy from ASPEN Suggests Reduced Mucus Plugging and Modest Airway Change
A 100‑patient CT substudy from the ASPEN program found that brensocatib, especially the 25‑mg dose, reduced mucus plugging and increased healthy parenchyma at 52 weeks, providing preliminary imaging evidence that it may modify disease biology in noncystic fibrosis bronchiectasis.
